Abstract
Since the launch of the qualification process in 2009, the CHMP reviewed/is reviewing 48 requests for qualification advice or opinion (as of Sept 2013) related to biomarkers (BM) or other novel drug development tools (e.g. patient reported outcome measures, modeling, and statistical methods). The qualification opinions are available on the EMA website (Qualification of novel methodologies for medicine development, http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000319.jsp&mid=WC0b01ac0580022bb0#section2, 2013). Also there is a trend of increasing numbers of qualification requests to CHMP, indicative of the pace that targeted drug development and personalized medicine is gaining and the need to bring the new tools from research to drug development and clinical use. This chapter will focus on the regulatory experience gained so far from the CHMP qualification procedure. Basic qualification principles will be presented. Through qualification examples, we will elaborate on common grounds and divergences between the different stakeholders.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mischak H, Ioannidis JP, Argiles A et al (2012) Implementation of proteomic biomarkers: making it work. Eur J Clin Invest 42:1027–1036
Qualification of novel methodologies for medicine development. http://www.ema.europa.eu/ema/index.jsp?curl=pages/regulation/document_listing/document_listing_000319.jsp&mid=WC0b01ac0580022bb0#section2. Accessed 30 Sept 2013
EMA workshops on biomarkers. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2009/11/event_detail_000077.jsp&mid=WC0b01ac058004d5c3. http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/events/2009/11/event_detail_000082.jsp&mid=WC0b01ac058004d5c3. Accessed 30 Sept 2013
Manolis E, Vamvakas S, Isaac M (2011) New pathway for qualification of novel methodologies in the European Medicines Agency. Proteomics Clin Appl 5:248–255
International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use concept paper on pharmacogenomic biomarker qualification: format and data standards. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003863.pdf. Accessed 30 Sept 2013
Guideline on clinical evaluation of diagnostic agents. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003580.pdf. Accessed 30 Sept 2013
Reflection paper on pharmacogenomic samples, testing and data handling. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003864.pdf. Accessed 30 Sept 2013
Reflection paper on co-development of pharmacogenomic biomarkers and assays in the context of drug development. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2010/07/WC500094445.pdf. Accessed 30 Sept 2013
Ziegler A, Koch A, Krockenberger K et al (2012) Personalized medicine using DNA biomarkers: a review. Hum Genet 131:1627–1638
ICH topic E 9 statistical principles for clinical trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf. Accessed 30 Sept 2013
http://www.cdisc.org/. Accessed 30 Sept 2013
EMA points to consider on application with 1. meta-analysis; 2. one pivotal study. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003657.pdf. Accessed 30 Sept 2013
Reflection paper on risk based quality management in clinical trials. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/08/WC500110059.pdf. Accessed 30 Sept 2013
Qualification opinion ILSI/HESI submission of novel renal biomarkers for toxicity. http://www.ema.europa.eu/docs/en_GB/document_library/Regulatory_and_procedural_guideline/2010/11/WC500099359.pdf. Accessed 30 Sept 2013
Disclaimer
The views expressed in this article are the personal views of the author(s) and may not be understood or quoted as being made on behalf of or reflecting the position of the EMA or one of its committees or working parties.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this protocol
Cite this protocol
Manolis, E., Koch, A., Deforce, D., Vamvakas, S. (2015). The European Medicines Agency Experience with Biomarker Qualification. In: Vlahou, A., Makridakis, M. (eds) Clinical Proteomics. Methods in Molecular Biology, vol 1243. Humana Press, New York, NY. https://doi.org/10.1007/978-1-4939-1872-0_15
Download citation
DOI: https://doi.org/10.1007/978-1-4939-1872-0_15
Published:
Publisher Name: Humana Press, New York, NY
Print ISBN: 978-1-4939-1871-3
Online ISBN: 978-1-4939-1872-0
eBook Packages: Springer Protocols